{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T10:07:55Z","timestamp":1784196475701,"version":"3.55.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T00:00:00Z","timestamp":1772668800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","endocrinologydiabetes.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["AACE Endocrinology and Diabetes"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.aed.2026.03.002","type":"journal-article","created":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T17:05:09Z","timestamp":1773162309000},"page":"630-632","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Sulpiride-Induced Severe Hyperprolactinemia in an IBS Patient: A Case Report From Saudi Arabia"],"prefix":"10.1016","volume":"13","author":[{"given":"Adel","family":"Alghamdi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thekra","family":"Alsalmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Alzahrani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asma","family":"Alazwari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.aed.2026.03.002_bib1","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1210\/jc.2010-1692","article-title":"Diagnosis and treatment of hyperprolactinemia: an endocrine society clinical practice guideline","volume":"96","author":"Melmed","year":"2011","journal-title":"J Clin Endocr Metab"},{"key":"10.1016\/j.aed.2026.03.002_bib2","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.psychres.2016.03.015","article-title":"Prolactin and macroprolactin levels in psychiatric patients receiving atypical antipsychotics: a preliminary study","volume":"239","author":"Park","year":"2016","journal-title":"Psychiatry Res"},{"key":"10.1016\/j.aed.2026.03.002_bib3","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/j.1365-2265.2006.02562.x","article-title":"Guidelines of the pituitary society for the diagnosis and management of prolactinomas","volume":"65","author":"Casanueva","year":"2006","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.aed.2026.03.002_bib4","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ecl.2007.10.013","article-title":"Hyperprolactinemia and prolactinomas","volume":"37","author":"Mancini","year":"2008","journal-title":"Endocrinol Metab Clin North Am"},{"key":"10.1016\/j.aed.2026.03.002_bib5","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1007\/BF03346388","article-title":"Diagnosis and management of hyperprolactinemia: results of a Brazilian multicenter study with 1234 patients","volume":"31","author":"Vilar","year":"2008","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.aed.2026.03.002_bib6","first-page":"425","article-title":"Risperidone-associated hyperprolactinemia","volume":"6","author":"Kearns","year":"2000","journal-title":"EndocrPract"},{"key":"10.1016\/j.aed.2026.03.002_bib7","first-page":"127","article-title":"Guidelines for the diagnosis and treatment of hyperprolactinemia","volume":"94","author":"Biller","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.aed.2026.03.002_bib8","first-page":"83","article-title":"New medical approaches in pituitary adenomas","volume":"32","author":"Colao","year":"2004","journal-title":"Front Horm Res"},{"key":"10.1016\/j.aed.2026.03.002_bib9","first-page":"341","article-title":"Management of hyperprolactinemia in postmenopausal women","volume":"76","author":"Bronstein","year":"2012","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.aed.2026.03.002_bib10","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1080\/13651501.2018.1425459","article-title":"Prevalence and risk factors of hyperprolactinemia among patients with various psychiatric diagnoses and medications","volume":"22","author":"Alosaimi","year":"2018","journal-title":"Int J Psychiatry Clin Pract"},{"issue":"5_suppl","key":"10.1016\/j.aed.2026.03.002_bib11","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1177\/0269881112442016","article-title":"Prolactin, hyperprolactinaemia and antipsychotic treatment: a review and lessons for treatment of early psychosis","volume":"26","author":"Cookson","year":"2012","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.aed.2026.03.002_bib13","doi-asserted-by":"crossref","first-page":"769","DOI":"10.9758\/cpn.23.1057","article-title":"Prolactin level changes according to atypical antipsychotics use: a study based on clinical data warehouse","volume":"21","author":"Kim","year":"2023","journal-title":"Clin Psychopharmacol Neurosci"},{"key":"10.1016\/j.aed.2026.03.002_bib14","doi-asserted-by":"crossref","first-page":"355","DOI":"10.4103\/ijem.IJEM_555_16","article-title":"Levosulpiride and serum prolactin levels","volume":"21","author":"Kuchay","year":"2017","journal-title":"Indian J Endocrinol Metab"},{"key":"10.1016\/j.aed.2026.03.002_bib15","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1471-244X-10-26","article-title":"Effectiveness of second-generation antipsychotics: a naturalistic, randomized comparison of olanzapine, quetiapine, risperidone, and ziprasidone","volume":"10","author":"Johnsen","year":"2010","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.aed.2026.03.002_bib16","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1002\/hup.1116","article-title":"Hyperprolactinemia associated with psychotropics\u2014a review","volume":"25","author":"Madhusoodanan","year":"2010","journal-title":"Hum Psychopharmacol Clin Exp"},{"key":"10.1016\/j.aed.2026.03.002_bib17","doi-asserted-by":"crossref","first-page":"563","DOI":"10.2165\/11533140-000000000-00000","article-title":"Antidepressant-induced hyperprolactinaemia: incidence, mechanisms and management","volume":"24","author":"Coker","year":"2010","journal-title":"CNS Drugs"},{"key":"10.1016\/j.aed.2026.03.002_bib18","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.jad.2019.03.006","article-title":"Aripiprazole for the treatment of duloxetine-induced hyperprolactinemia: a case report","volume":"250","author":"Luo","year":"2019","journal-title":"J Affect Disord"},{"key":"10.1016\/j.aed.2026.03.002_bib19","series-title":"Endotext [Internet]","article-title":"Pharmacological causes of hyperprolactinemia","author":"Kolnikaj","year":"2024"},{"key":"10.1016\/j.aed.2026.03.002_bib20","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.psym.2013.08.008","article-title":"Psychotropic-induced hyperprolactinemia: a clinical review","volume":"55","author":"Ajmal","year":"2014","journal-title":"Psychosomatics"},{"key":"10.1016\/j.aed.2026.03.002_bib21","first-page":"500","article-title":"Hyperprolactinemia induced by indoramin","volume":"53","author":"Pradalier","year":"1998","journal-title":"Therapie"},{"key":"10.1016\/j.aed.2026.03.002_bib22","doi-asserted-by":"crossref","first-page":"165","DOI":"10.4103\/0972-4958.127383","article-title":"Cimetidine-induced hyperprolactinemia","volume":"27","author":"Singh","year":"2013","journal-title":"J Med Soc"},{"key":"10.1016\/j.aed.2026.03.002_bib23","unstructured":"Ashfaq M. Delineating Biochemical Interaction Between Proton Pump Inhibitors and Hyperprolactinemia in Patient Population (Doctoral dissertation, COMSATS University, Islamabad)."},{"key":"10.1016\/j.aed.2026.03.002_bib24","series-title":"Pituitary Disorders throughout the Life Cycle: A Case-Based Guide","first-page":"341","article-title":"Opioid interference with hypothalamic-pituitary function","author":"Hakami","year":"2022"},{"key":"10.1016\/j.aed.2026.03.002_bib25","first-page":"929","article-title":"Pharmacological causes of hyperprolactinemia","volume":"3","author":"Torre","year":"2007","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.aed.2026.03.002_bib26","first-page":"1223","article-title":"Risk of hyperprolactinemia during treatment with carbamazepine","volume":"46","author":"Hadj","year":"2023","journal-title":"Drug Saf"},{"issue":"4","key":"10.1016\/j.aed.2026.03.002_bib27","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2017.56","article-title":"Effects of dopamine D2\/D3 receptor antagonism on human planning and spatial working memory","volume":"7","author":"Naef","year":"2017","journal-title":"Translational Psychiatry"},{"key":"10.1016\/j.aed.2026.03.002_bib28","doi-asserted-by":"crossref","DOI":"10.1017\/pen.2020.7","article-title":"A low dosage of the dopamine D2-receptor antagonist sulpiride affects effort allocation for reward regardless of trait extraversion","volume":"3","author":"Ohmann","year":"2020","journal-title":"Personal Neuroscience"},{"key":"10.1016\/j.aed.2026.03.002_bib29","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1055\/s-0043-107243","article-title":"Hyperprolactinemia and the association with all-cause mortality and cardiovascular mortality","volume":"49","author":"Krogh","year":"2017","journal-title":"Horm Metab Res"},{"issue":"3","key":"10.1016\/j.aed.2026.03.002_bib12","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s00213-004-1826-6","article-title":"Prolactinemia is uncoupled from central D2\/D3 dopamine receptor occupancy in amisulpride treated patients","volume":"175","author":"Bressan","year":"2004","journal-title":"Psychopharmacology"}],"container-title":["AACE Endocrinology and Diabetes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3050915726000603?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3050915726000603?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T09:36:38Z","timestamp":1784194598000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S3050915726000603"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S3050915726000603"],"URL":"https:\/\/doi.org\/10.1016\/j.aed.2026.03.002","relation":{},"ISSN":["3050-9157"],"issn-type":[{"value":"3050-9157","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sulpiride-Induced Severe Hyperprolactinemia in an IBS Patient: A Case Report From Saudi Arabia","name":"articletitle","label":"Article Title"},{"value":"AACE Endocrinology and Diabetes","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.aed.2026.03.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of American Association of Clinical Endocrinology.","name":"copyright","label":"Copyright"}]}}